Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim.

Abstract:

:Bronchiolitis obliterans organizing pneumonia (BOOP) presents with fever, dyspnoea, pleuritic chest pain and hypoxia. The diagnosis can be made from radiological appearances on chest radiograph and CT scan correlated with histological findings following biopsy. We present a 52-year-old gentleman undergoing treatment for high grade non-Hodgkin's lymphoma who developed respiratory symptoms during chemotherapy. BOOP was diagnosed and he responded well to oral prednisolone. The cause of BOOP is often not certain. However, in this case we suspect pegylated filgrastim or rituximab as possible agents.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Macartney C,Burke E,Elborn S,Magee N,Noone P,Gleadhill I,Allen D,Kettle P,Drake M

doi

10.1080/10428190500144615

keywords:

subject

Has Abstract

pub_date

2005-10-01 00:00:00

pages

1523-6

issue

10

eissn

1042-8194

issn

1029-2403

pii

N5736038455303JK

journal_volume

46

pub_type

杂志文章
  • Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.

    abstract::Peripheral blood progenitor cells are being used increasingly as part of the treatment protocol for a variety of haematological malignancies. The most appropriate mobilisation therapy and the optimum collection procedures have yet to be fully elucidated. 28 patients with myeloma (9), NHL (11) and HD (8) underwent PBSC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509112208

    authors: Scott MA,Ager S,Apperley JF,Jestice HK,Bloxham DM,Boraks P,Mahendra P,Marcus RE

    更新日期:1995-11-01 00:00:00

  • Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.

    abstract::The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.588761

    authors: Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

    更新日期:2011-10-01 00:00:00

  • Novel agents versus chemotherapy as frontline treatment of CLL.

    abstract::Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1280606

    authors: Piggin A,Bayly E,Tam CS

    更新日期:2017-06-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract::Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600565057

    authors: Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期:2006-06-01 00:00:00

  • Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

    abstract::Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P < 0.05) serum matrix metalloproteinase (MMP) 9 an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902889270

    authors: Negaard HF,Svennevig K,Kolset SO,Iversen N,Lothe IM,Østenstad B,Sandset PM,Iversen PO

    更新日期:2009-06-01 00:00:00

  • The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal.

    abstract::According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.780653

    authors: Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

    更新日期:2013-11-01 00:00:00

  • MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.

    abstract::A prospective randomized study on aggressive non-Hodgkin's lymphomas was conducted by investigators at several Italian institutions with the intent of comparing two third-generation conceptually different regimens: the regimen containing methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428199509054434

    authors: Mazza P,Zinzani PL,Martelli M,Fiacchini M,Bocchia M,Pileri S,Falini B,Martelli MF,Amadori S,Papa G

    更新日期:1995-02-01 00:00:00

  • Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

    abstract::Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1594212

    authors: Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

    更新日期:2019-10-01 00:00:00

  • Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH Dependency.

    abstract::We have studied the effect of dimethyl-sulfoxide(DMSO)-induced granulocytic differentiation on the sensitivity of HL-60 cells to various cytotoxic topoisomerase II inhibitors: (i) undifferentiated HL-60 cells are highly sensitive to etoposide, while differentiated HL-60 cells are 700-1000 fold resistant to etoposide, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068137

    authors: Gieseler F,Boege F,Biersack H,Spohn B,Clark M,Wilms K

    更新日期:1991-01-01 00:00:00

  • Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival.

    abstract::We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609045722

    authors: Bosanquet AG,Bell PB,Burlton AR,Amos TA

    更新日期:1996-12-01 00:00:00

  • Apoptosis inducing novel anti-leukemic agent, bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV) [VO(SO4)(Me2-Phen)2] depolarizes mitochondrial membranes.

    abstract::Bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV) [VO(SO(4) )(Me(2)-Phen)(2)] induces apoptosis in human NALM-6 leukemia cells. In the present report, we demonstrate that VO(SO(4) )(Me(2)-Phen)(2)-induced apoptosis is mediated through the generation of reactive oxygen species (ROS), depletion of glutathione...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109060353

    authors: Narla RK,Dong Y,Uckun FM

    更新日期:2001-05-01 00:00:00

  • Epstein-Barr virus (EBV)-induced B-cell proliferative disorder after chemotherapy in a patient with hemophagocytic lymphohistiocytosis with associated EBV-induced T-cell proliferation.

    abstract::We report a case of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) which developed after chemotherapy for hemophagocytic lymphohistiocytosis (HLH), who had no history of immunodeficiency or familial X-linked LPD. In HLH, the presence of EBV in T-cells was confirmed by a combination of in situ h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009058512

    authors: Suzumiya J,Ohshima K,Kanda M,Kumagawa M,Nagano M,Hirata M,Nawa Y,Tamura K,Kikuchi M

    更新日期:2000-05-01 00:00:00

  • CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.

    abstract::Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500052156

    authors: Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

    更新日期:2005-05-01 00:00:00

  • Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.

    abstract::The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609054816

    authors: Horowitz HW,Holmgren D,Seiter K

    更新日期:1996-09-01 00:00:00

  • The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.

    abstract::Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819042000206687

    authors: Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

    更新日期:2004-08-01 00:00:00

  • Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.

    abstract::One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272767

    authors: Swerts K,de Moerloose B,Dhooge C,Noens L,Laureys G,Benoit Y,Philippé J

    更新日期:2004-11-01 00:00:00

  • NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

    abstract::The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1023799

    authors: Chattopadhyay A,Abecassis I,Redner RL

    更新日期:2015-01-01 00:00:00

  • Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs.

    abstract::An early intensive anthracycline therapy can improve therapeutic outcome in adult acute lymphoblastic leukaemia (ALL) but is usually associated with marked myelosuppressive effects and significant morbidity by infections. To reduce this risk, we employed granulocyte colony-stimulating factor (G-CSF, filgrastim 5 micro...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709109170

    authors: Bassan R,Lerede T,Di Bona E,Rossi G,Pogliani E,Rambaldi A,Buelli M,Viero P,Rodeghiero F,Izzi T,Corneo G,Barbui T

    更新日期:1997-06-01 00:00:00

  • Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies.

    abstract::Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400007524

    authors: Molica S

    更新日期:2005-01-01 00:00:00

  • Pruritus in pediatric non-Hodgkin's lymphoma.

    abstract::A two-year-old girl presented with a 3-month history of generalized pruritus. One week before hospitalization she developed a superior vena cava syndrome and obstruction of the upper airways. Clinical and laboratory findings included generalized lymphadenopathy, a mediastinal mass compressing the tracheal lumen to the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006330

    authors: Vècsei A,Attarbaschi A,Krammer U,Mann G,Gadner H

    更新日期:2002-09-01 00:00:00

  • Fifty years of hairy cell leukemia treatments.

    abstract::Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.565094

    authors: Golomb HM

    更新日期:2011-06-01 00:00:00

  • Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

    abstract::During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109060343

    authors: Lindauer M,Fischer T

    更新日期:2001-05-01 00:00:00

  • Clinicopathological analysis of follicular lymphoma with a polyploid karyotype.

    abstract::The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809092694

    authors: James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

    更新日期:1998-01-01 00:00:00

  • Current and future immunotherapeutic approaches in Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1185789

    authors: Bröckelmann PJ,Borchmann P,Engert A

    更新日期:2016-09-01 00:00:00

  • In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.

    abstract::P-glycoprotein(P-gp)- related resistance is one of the major obstacles in treating leukemia patients. Therefore, it is of clinical interest to find new potential modulators and compare their P-gp-modulating efficacy. The present analysis investigated the influence of P-gp modulators, such as verapamil, tamoxifen, drol...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057619

    authors: Nüssler V,Pelka-Fleisc R,Gieseler F,Hasmann M,Löser R,Gullis E,Stötzer O,Zwierzina H,Wilmanns W

    更新日期:1998-11-01 00:00:00

  • Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.

    abstract::We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (wh...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864354

    authors: Middeke JM,Teipel R,Röllig C,Stasik S,Zebisch A,Sill H,Kramer M,Scholl S,Hochhaus A,Jost E,Brümmendorf TH,Naumann R,Steffen B,Serve H,Altmann H,Kunzmann V,Einsele H,Parmentier S,Schaich M,Burchert A,Neubauer A,S

    更新日期:2021-01-05 00:00:00

  • Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.

    abstract::We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients wer...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819031000067729

    authors: Avilés A,Cleto S,Neri N,Huerta-Guzmán J,Talavera A,Castañeda C,González M

    更新日期:2003-08-01 00:00:00

  • Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population.

    abstract::The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.628062

    authors: Huang L,Huang J,Wu P,Li Q,Rong L,Xue Y,Lu Q,Li J,Tong N,Wang M,Zhang Z,Fang Y

    更新日期:2012-05-01 00:00:00

  • Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia.

    abstract::There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.606938

    authors: Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

    更新日期:2012-02-01 00:00:00

  • Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.

    abstract::We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809068569

    authors: Myers DE,Sicheneder A,Clementson D,Dvorak N,Venkatachalam T,Sev AR,Chandan-Langlie M,Uckun FM

    更新日期:1998-04-01 00:00:00